The market is already served: free apps give these buyers offline drug references, and a one-time-purchase handbook exists. The one buyer quoted is switching to a free app, not looking to pay anyone. Read as a verdict, that is a stop for this idea as pitched.
The run cost a short wait instead of weeks of building, and the sources above are yours to check.
What you could do next
- Drop it
- This is what the evidence supports.
- Ask a narrower question
- A single specialty, or a country the listed apps do not cover, as a new check. Look for buyers who ask for it in their own words.
How a verdict is reached, and where it can go wrong, is on how it works.